DrugPatentWatch Database Preview

Details for Patent: 7,635,704

Email this page to a colleague

« Back to Dashboard

Which drugs does patent 7,635,704 protect, and when does it expire?

Patent 7,635,704 protects GENVOYA, STRIBILD, and VITEKTA, and is included in three NDAs.

This patent has thirty-seven patent family members in twenty-seven countries.

Summary for Patent: 7,635,704

Title:	Stable crystal of 4-oxoquinoline compound
Abstract:	Provision of a stabilized crystal of 6-(3-chloro-2-fluorobenzyl)-1-[(S)-1-hydroxymethyl-2-methylpropyl]-7-meth- oxy-4-oxo-1, 4-dihydroquinoline-3-carboxylic acid (compound A). A crystal of compound A, which shows a particular X-ray powder diffraction pattern of a characteristic diffraction peaks at diffraction angles 2.theta.(.degree.) as measured by X-ray powder diffractmetry.
Inventor(s):	Satoh; Motohide (Osaka, JP), Motomura; Takahisa (Osaka, JP), Matsuda; Takashi (Osaka, JP), Kondo; Kentaro (Osaka, JP), Ando; Koji (Osaka, JP), Matsuda; Koji (Osaka, JP), Miyake; Shuji (Osaka, JP), Uehara; Hideto (Osaka, JP)
Assignee:	Japan Tobacco Inc. (Tokyo, JP)
Application Number:	11/133,471
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 7,635,704
Patent Claim Types: see list of patent claims	Compound; Composition; Dosage form; Use;

Drugs Protected by US Patent 7,635,704

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Gilead Sciences Inc	GENVOYA	cobicistat; elvitegravir; emtricitabine; tenofovir alafenamide fumarate	TABLET;ORAL	207561-001	Nov 5, 2015		RX	Yes	Yes			Y	Y		TREATMENT OF HIV INFECTION
Gilead Sciences Inc	STRIBILD	cobicistat; elvitegravir; emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	203100-001	Aug 27, 2012		RX	Yes	Yes			Y	Y		TREATMENT OF HIV INFECTION
Gilead Sciences Inc	VITEKTA	elvitegravir	TABLET;ORAL	203093-001	Sep 24, 2014		DISCN	Yes	No			Y	Y		TREATMENT OF HIV INFECTION
Gilead Sciences Inc	VITEKTA	elvitegravir	TABLET;ORAL	203093-002	Sep 24, 2014		DISCN	Yes	No			Y	Y		TREATMENT OF HIV INFECTION

Foreign Priority and PCT Information for Patent: 7,635,704

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2004-150979	May 20, 2004

International Family Members for US Patent 7,635,704

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	049280
Argentina	096100
Australia	2005245296
Brazil	PI0510114